Abstract
The biodistribution of radiolabeled mouse anti-pan T monoclonal antibody (W313) against rat lymphocytes was examined in normal rats. Monoclonal antibody to human prostate-associated antigens (PAA) served as a control. In vitro studies demonstrated a 38% maximum binding of radiolabeled W313 to lymphocytes, which was significant (P < 0.001) when compared with the control (PAA) value of 3.4%. In vivo, intravenously administered 111In labeled W313 and 131I labeled W313 exhibited similar tissue distribution patterns. The localization of W313 in lymphoid tissue was significantly greater than that achieved with PAA. W313, however, did not demonstrate significant localization in the intact thymus and accumulated to a higher degree (6–10% ID/g) than expected in bone marrow at 24 h. These findings suggest that radiolabeled anti-lymphocyte monoclonal antibodies may not be well suited for the treatment of lymphoreticular neoplasms and allograft rejection in patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
